文献速递技术与安全CT

换用替代碘对比剂以预防其相关不良药物反应复发:一项Meta分析

Substituting with alternative iodinated contrast medium to prevent recurrent adverse drug reactions associated with its use: a meta-analysis.
PubMed 文献 · Eur Radiol · 2024-10-18

该系统综述与Meta分析纳入10篇原始文献,评估碘对比剂相关不良药物反应(ADR)的复发率及换用缺乏共同氨甲酰侧链的替代碘对比剂的预防效果。碘对比剂相关ADR与超敏反应的合并复发率无显著差异(16.6% vs 15.5%,p=0.87)。换用不同碘对比剂较使用相同碘对比剂,复发ADR的合并OR为0.31(95%CI 0.21-0.45),相当于降低69%;换用不同侧链碘对比剂较换用共同侧链碘对比剂,合并OR为0.65(95%CI 0.52-0.82),相当于额外降低35%。

要点

  • 换用不同碘对比剂可使复发ADR降低69%(OR 0.31,95%CI 0.21-0.45)。
  • 换用缺乏共同氨甲酰侧链的碘对比剂较换用共同侧链者额外降低35%(OR 0.65,95%CI 0.52-0.82)。
  • 碘对比剂相关ADR与超敏反应的合并复发率无显著差异(16.6% vs 15.5%,p=0.87)。

核心结论

  • 换用替代碘对比剂可使复发ADR降低69%,若替代碘对比剂缺乏共同氨甲酰侧链则额外降低35%。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE和EMBASE数据库,纳入10篇原始文献,文献时间跨度为2001年6月至2021年3月,首次检索于2023年11月10日进行;纳入后续接受增强CT扫描的索引反应患者,排除重叠队列;采用DerSimonian-Laird随机效应模型计算合并复发率。

诊断标准与关键数值

  • 碘对比剂相关ADR合并复发率为16.6%(95%CI 7.8-31.9%),碘对比剂相关超敏反应合并复发率为15.5%(95%CI 10.8-21.8%),两者无显著差异(p=0.87)。
  • 换用不同碘对比剂较使用相同碘对比剂,复发ADR的合并OR为0.31(95%CI 0.21-0.45),相当于降低69%。
  • 换用不同侧链碘对比剂较换用共同侧链碘对比剂,复发ADR的合并OR为0.65(95%CI 0.52-0.82),相当于额外降低35%。

临床应用与阅片要点

  • 作者倡导对有此类事件史的患者使用缺乏共同氨甲酰侧链的替代碘对比剂以预防不良药物反应复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To systematically review and meta-analyze the recurrent rate of iodinated contrast medium (ICM)-associated adverse drug reactions (ADRs) and the preventive effect of using alternative ICM lacking a common carbamoyl side chain.

MATERIALS AND METHODS: A systematic literature search was conducted in the MEDLINE and EMBASE databases to identify studies that investigated the recurrence rate of ICM-associated ADRs or hypersensitivity reactions (HSRs). Studies that included patients who subsequently underwent contrast-enhanced computed tomography scans after their index reactions were included, while studies with overlapping cohorts were excluded. The first search was conducted on November 10, 2023. The pooled recurrence rate of ICM-associated ADR was determined using the DerSimonian-Laird random-effects model. Subgroup analyses were also conducted based on the substitution of ICM, with particular consideration given to the N-(2,3-dihydroxypropyl) carbamoyl side chain.

RESULTS: A total of ten original articles were included in the analysis, collectively spanning from June 2001 to March 2021. The pooled recurrence rate of ICM-associated ADR was not significantly different from that of ICM-associated HSR (16.6% [95% CI, 7.8-31.9%] vs. 15.5% [95% CI, 10.8-21.8%], p = 0.87). In the subgroup analyses, the pooled odds ratio for ICM-associated recurrent ADR when using a different ICM compared with using the same ICM was 0.31 (95% CI, 0.21-0.45), which means a 69% reduction. Moreover, the pooled odds ratio for ICM-associated recurrent ADR when substituting ICMs with different side chains compared with substituting with common side chains was 0.65 (95% CI, 0.52-0.82), which means an additional 35% reduction.

CONCLUSION: Substituting with an alternative ICM led to a 69% reduction in recurrent ADRs, with an additional 35% reduction observed when using ICM lacking a common carbamoyl side chain.

KEY POINTS: Question No standardized guidelines exist for replacing previously used iodinated contrast medium (ICM) to prevent recurrent adverse reactions. Findings Using alternative contrast medium with a different carbamoyl side chain prevents adverse drug reactions effectively. Clinical relevance This study advocates using alternative ICM without a common carbamoyl side chain to prevent recurrent adverse drug reactions in patients with a history of such events.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Lim SJ, Suh PS, Suh CH, et al. Substituting with alternative iodinated contrast medium to prevent recurrent adverse drug reactions associated with its use: a meta-analysis. Eur Radiol. 2024. PMID: 39419863. doi:10.1007/s00330-024-11114-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。